Pharma layoffs continue to roil U.K.

In Europe, pharma restructuring has hit the U.K. hardest, industry experts say, with British drugmakers cutting 11 percent to 15 percent of its jobs across the board over the past two years--and the cuts aren't over yet. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.